Basilea reports positive interim results from phase 2 study FIDES-01 for derazantinib in FGFR2 gene mutation- or amplification-positive patients with bile duct cancer (iCCA)

Joey Cohen
Medication Adherence

Brenda Snow
Authentic Patient Voice

Frank Burrell
Scientific Storytelling

Daniel Sontupe
Market Access

Matt Turner
Patient Affordability

Bud Bilanich
Success Coach

Amy Giles
Increasing Engagement

Liz Kane
Impactful Strategy

David Linetsky
Point-of-Care Marketing

Paul Theisen
Patient Acquisition

Matthew Durham
Omnidynamic Marketing

Suma Ramadas, PhD
Medical Affairs

Pat Purcell
Meeting Engagement

Stacey Gandler
Brand Nourishment